|
Research Management and Support
|
RMS ES 2018
|
$340,640,887
|
$108,000
|
N/A
|
National Institutes of Health
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-05S1
|
$2,256,906
|
$180,552
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Solid Malignancy Integrated Translational Science Center
|
5U10CA180884-05
|
$192,024
|
$38,405
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-05
|
$20,853,800
|
$1,668,304
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S1
|
$142,498
|
$1,425
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S2
|
$200,000
|
$2,000
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
5P30CA010815-49
|
$2,645,581
|
$26,456
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Elucidating transcription regulation by epigenetics in neuroblastoma
|
1K08CA226237-01
|
$206,394
|
$206,394
|
APPLEBAUM, MARK
|
UNIVERSITY OF CHICAGO
|
|
Childhood Cancer Survivor Study
|
3U24CA055727-24S1
|
$120,439
|
$12,044
|
ARMSTRONG, GREGORY
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Childhood Cancer Survivor Study
|
5U24CA055727-24
|
$4,218,764
|
$421,876
|
ARMSTRONG, GREGORY
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Cancer Center Support Grant
|
2P30CA082103-19
|
$7,954,381
|
$79,544
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-19S1
|
$84,000
|
$840
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-19S2
|
$206,488
|
$2,065
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-19S3
|
$257,838
|
$2,578
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Novel ODC Inhibitor Phaseolotoxin in Neuroblastoma
|
1R21CA216867-01A1
|
$193,750
|
$193,750
|
BACHMANN, ANDRE
|
MICHIGAN STATE UNIVERSITY
|
|
UW Comprehensive CANCER CENTER SUPPORT
|
2P30CA014520-44
|
$4,590,130
|
$91,803
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive CANCER CENTER SUPPORT
|
3P30CA014520-44S1
|
$250,000
|
$5,000
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive CANCER CENTER SUPPORT
|
3P30CA014520-44S2
|
$136,232
|
$2,725
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive CANCER CENTER SUPPORT
|
3P30CA014520-44S3
|
$75,711
|
$1,514
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive CANCER CENTER SUPPORT
|
3P30CA014520-44S4
|
$31,772
|
$635
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
Targeting the GPC2 oncoprotein with immune-based therapies in neuroblastoma
|
1K08CA230223-01
|
$202,195
|
$202,195
|
BOSSE, KRISTOPHER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Cancer Center Support Grant
|
3P30CA016058-42S1
|
$59,783
|
$3,587
|
CALIGIURI, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
Combining hu14.18-IL2 and NK cell infusions to treat neuroblastoma
|
1R01CA215461-01A1
|
$347,078
|
$347,078
|
CAPITINI, CHRISTIAN
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
Exploiting resistance mechanisms to RAS-MAPK inhibition in relapsed neuroblastoma
|
1F31CA220844-01A1
|
$44,524
|
$44,524
|
COGGINS, GRACE
|
UNIVERSITY OF PENNSYLVANIA
|
|
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT
|
3P30CA134274-11S1
|
$629,550
|
$31,478
|
CULLEN, KEVIN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT
|
3P30CA134274-11S2
|
$200,000
|
$10,000
|
CULLEN, KEVIN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT
|
3P30CA134274-11S3
|
$125,000
|
$6,250
|
CULLEN, KEVIN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT
|
5P30CA134274-11
|
$2,266,216
|
$113,311
|
CULLEN, KEVIN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-10S1
|
$72,918
|
$729
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-10S2
|
$200,473
|
$2,005
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-10S3
|
$234,000
|
$2,340
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
5P30CA138292-10
|
$2,574,000
|
$25,740
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Myc - Transcription and Apoptosis
|
5R01CA051497-28
|
$382,892
|
$191,446
|
DANG, CHI
|
WISTAR INSTITUTE
|
|
Exosomes in tumor cell-mesenchymal stromal cell interaction
|
5R01CA207983-02
|
$449,691
|
$314,784
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Training Physician Scientists in Pediatric Oncology
|
5T32CA009659-23
|
$214,456
|
$107,228
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Discovering the genetic basis of neuroblastoma initiation and progression
|
1R03CA230366-01
|
$172,000
|
$172,000
|
DISKIN, SHARON
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Structural Variation in Neuroblastoma
|
5R01CA204974-03
|
$384,300
|
$384,300
|
DISKIN, SHARON
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Tumor and host markers of clinical outcomes after MIBG therapy in neuroblastoma
|
1R01CA214912-01A1
|
$629,914
|
$629,914
|
DUBOIS, STEVEN
|
DANA-FARBER CANCER INST
|
|
Employing the Myc Transcriptional Network to Reveal Oncogenic Pathways
|
5R01CA057138-27
|
$635,460
|
$317,730
|
EISENMAN, ROBERT
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Clinical significance and mechanism of action of exosomal microRNAs in Neuroblastoma chemoresistance.
|
1R01CA219024-01A1
|
$123,772
|
$123,772
|
FABBRI, MULLER
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Role of microRNAs released by Tumor Associated Macrophages within Exosomes in the chemoresistance of Neuroblastoma
|
7R01CA215753-02
|
$340,118
|
$340,118
|
FABBRI, MULLER
|
UNIVERSITY OF HAWAII AT MANOA
|
|
Clinical significance and mechanism of action of exosomal microRNAs in Neuroblastoma chemoresistance.
|
7R01CA219024-02
|
$262,816
|
$262,816
|
FABBRI, MULLER
|
UNIVERSITY OF HAWAII AT MANOA
|
|
ABT-199 based therapies to treat neuroblastoma
|
5R01CA215610-02
|
$359,846
|
$359,846
|
FABER, ANTHONY
|
VIRGINIA COMMONWEALTH UNIVERSITY
|
|
USC Norris Comprehensive Cancer Center (Core) Grant
|
3P30CA014089-43S1
|
$40,593
|
$5,683
|
FARNHAM, PEGGY
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC Norris Comprehensive Cancer Center (Core) Grant
|
5P30CA014089-43
|
$6,268,475
|
$877,587
|
FARNHAM, PEGGY
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
Dissecting the contribution of the transcriptional regulators of SNS fate to neuroblastoma oncogenesis
|
1R01CA216394-01A1
|
|
$0
|
FREEMAN, KEVIN
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Dissecting the contribution of the transcriptional regulators of SNS fate to neuroblastoma oncogenesis
|
7R01CA216394-02
|
$347,700
|
$347,700
|
FREEMAN, KEVIN
|
UNIVERSITY OF TENNESSEE HEALTH SCI CTR
|
|
The ALK receptor tyrosine kinase as a therapeutic target in neuroblastoma
|
5R01CA148688-07
|
$413,844
|
$413,844
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
|
Transcriptional CDKs as therapeutic targets in MYC-dependent cancers
|
5R01CA197336-03
|
$407,748
|
$407,748
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA015704-43S1
|
$78,024
|
$2,341
|
GILLILAND, D
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
Total relevant funding to Neuroblastoma for this search: $30,116,194
|